Global Implementation Status and Practical Challenges

It would be misleading to present IDMP and its supporting infrastructure as a finished, universally-adopted system, and this lesson exists specifically to correct that impression before it takes hold. Global adoption is genuinely uneven: the EU, through its SPOR programme, is furthest along in structurally implementing the full IDMP standard set; other major regions are at earlier, less complete stages of alignment, and continue to rely more heavily on WHO-DD or their own region-specific product coding conventions in day-to-day practice.

This unevenness creates a genuine, practical operational challenge for any global pharmaceutical company: maintaining product identification data compatible with several different systems simultaneously, rather than a single global standard everyone has already converged on. This echoes exactly the multi-framework reality Module 13 built for AI governance — CIOMS WG XIV, the EU AI Act, FDA-EMA Joint Principles, all applying with different specifics in different jurisdictions at once. Product identification, as of this course’s writing, sits in a genuinely comparable state: multiple overlapping systems, none of them universally sufficient on their own, requiring an organisation to satisfy several simultaneously.

Legacy data compounds the challenge in a way that’s easy to underestimate: decades of historical case data, recorded under older, less standardised product identification approaches, doesn’t automatically upgrade itself the moment a new standard like IDMP gets adopted. Retrofitting historical records with structurally sound IDMP-compliant identifiers is a genuinely significant data quality project in its own right — one many organisations are still actively working through rather than having already completed.

The honest, useful framing to carry forward from this lesson is that IDMP and its supporting infrastructure represent an actively evolving area of pharmacovigilance practice, not a settled, fully-implemented standard. Treating any specific claim about implementation status, timelines, or regional adoption as necessarily still accurate by the time you’re reading this is exactly the kind of overconfidence this course has warned against consistently — verify current specifics, the same discipline Module 13 built for citing AI platform capabilities, before relying on a claim in a live regulatory submission or presenting it confidently in an interview.